With the joint release and agreement of the PhRMA and EFPIA on those organizations clinical trial data sharing and transparency principles, BIO has releases its own Principles on Clinical Trial Data Sharing.
With the joint release and agreement of the PhRMA and EFPIA on those organizations clinical trial data sharing and transparency principles, BIO has releases its own Principles on Clinical Trial Data Sharing. Similar to the pharmaceutical members companies of PhRMA and EFPIA, BIO companies agree to the following:
1. Registering Clinical Trials: BIO member companies will register all company sponsored clinical trials conducted in patients in an appropriate public registry, such as ClinicalTrials.gov or the European Clinical Trials Database (EudraCT).
2. Summarizing the Results of Clinical Trials: BIO member companies will post technical summary results in a clinical trials database, with caveats.
3. Publishing Clinical Trials: BIO member companies will submit for publication in the scientific literature, or otherwise make available to the scientific community.
4. Providing Factual Summaries of Clinical Trials to Research Participants.
5. Responsibly Sharing Additional Clinical Trial Data. The difference here is that BIO member companies will develop and make public its procedures for this process, unlike the PhRMA/EFPIA principles, whose members companies agree to have requests reviewed by a separate scientific review board not employed by the company.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.